OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. [electronic resource]
Producer: 20170501Description: 2047-55 p. digitalISSN:- 1097-0215
- Acetanilides -- administration & dosage
- Animals
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Blood-Brain Barrier -- drug effects
- Brain Neoplasms -- drug therapy
- Camptothecin -- administration & dosage
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Dacarbazine -- administration & dosage
- Drug Synergism
- Everolimus -- administration & dosage
- Gene Expression Regulation, Neoplastic -- drug effects
- Glioblastoma -- drug therapy
- Heterocyclic Compounds, 3-Ring -- administration & dosage
- Humans
- Irinotecan
- Mice
- Temozolomide
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.